ROCHE acquired CAPP Medical, a genomics research company founded by members of Stanford University, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
CAPP Medical’s novel technology is designed to isolate and quantify small amounts of ctDNA through a blood draw, which can be used for cancer therapy selection and monitoring tumor response and resistance to therapy.
“Roche believes focused and high quality next generation sequencing assays using simple blood draws have the potential to significantly advance the time of cancer diagnosis and change routine cancer diagnostic monitoring and may be highly cost effective compared to today’s current standard of using PET and CT imaging to monitor tumor progression,” said Roland Diggelmann, COO of Roche Diagnostics.
CAPP Medical is a privately held company founded in October 2013. CAPP Medical’s technology focuses on assay design and the bioinformatics that allow for the detection of multiple mutations with a single assay.
